Key result
Blockade of the ICOS/ICOSL pathway during the immune response phase attenuated experimental autoimmune myocarditis development and suppressed cytokine expression.
Why the study?
Does blockade of the ICOS/ICOSL pathway attenuate experimental autoimmune myocarditis in Lewis rats?
Does blockade of the ICOS/ICOSL pathway attenuate experimental autoimmune myocarditis in Lewis rats?
Blockade of T cell activation through ICOS during the immune response phase attenuates experimental autoimmune myocarditis, suggesting ICOS as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
May support ICOS-targeted therapy development in myocarditis models; leaves open translation to human autoimmune disease.
Hideki Futamatsu (2003) studied Experimental autoimmune myocarditis. Anti-ICOS antibody or ICOS-immunoglobulin (ICOSIg) was evaluated on EAM development (evaluated by heart weight to body weight ratio, histological examination, and echocardiogram). Blockade of the ICOS/ICOSL pathway during the immune response phase attenuated experimental autoimmune myocarditis development and suppressed cytokine expression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: